Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Cancer Res
    November 2024
  1. MANDAL J, Jones TN, Liberto JM, Gaillard S, et al
    Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication.
    Cancer Res. 2024;84:3881-3893.
    >> Share

  2. HAANEN TJ, Boock S, Callahan CG, Peris I, et al
    Mutant PP2A Induces IGFBP2 Secretion to Promote Development of High-Grade Uterine Cancer.
    Cancer Res. 2024 Nov 12. doi: 10.1158/0008-5472.CAN-24-1263.
    >> Share

    October 2024
  3. DA COSTA AA, Somuncu O, Ravindranathan R, Mukkavalli S, et al
    Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.
    Cancer Res. 2024;84:3435-3446.
    >> Share

    August 2024
  4. SPEAR S, Le Saux O, Mirza HB, Iyer N, et al
    PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-3890.
    >> Share

    May 2024
  5. JOY JD, Malacrida B, Laforets F, Kotantaki P, et al
    Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
    Cancer Res. 2024 May 31. doi: 10.1158/0008-5472.CAN-23-3007.
    >> Share

    April 2024
  6. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
    Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
    >> Share

    March 2024
  7. RAMANARAYANAN V, Oberdoerffer P
    AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
    Cancer Res. 2024;84:793-795.
    >> Share

    January 2024
  8. HUANG TT, Chiang CY, Nair JR, Wilson KM, et al
    AKT1 interacts with DHX9 to mitigate R-loop-induced replication stress in ovarian cancer.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1908.
    >> Share

    December 2023
  9. HEO J, Kim YN, Shin S, Lee K, et al
    Serial circulating-tumor DNA analysis with a tumor naive next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429.
    >> Share

    October 2023
  10. BEDDOWS I, Fan H, Heinze K, Johnson BK, et al
    Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes.
    Cancer Res. 2023 Oct 24. doi: 10.1158/0008-5472.CAN-23-1362.
    >> Share

  11. ITO I, Yousef AMG, Chowdhury S, Dickson PN, et al
    Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
    Cancer Res. 2023;83:3184-3191.
    >> Share

    September 2023
  12. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    >> Share

    August 2023
  13. YU ZC, Li T, Tully E, Huang P, et al
    Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
    Cancer Res. 2023;83:2750-2762.
    >> Share

  14. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    >> Share

    July 2023
  15. WANG Y, Chen SY, Ta M, Senz J, et al
    Bi-allelic Dicer1 mutations in the gynecologic tract of mice drive lineage-specific development of DICER1 syndrome-associated cancer.
    Cancer Res. 2023 Jul 26:CAN-22-3620. doi: 10.1158/0008-5472.CAN-22-3620.
    >> Share

    June 2023
  16. LI QS, Zheng PS
    ESRRB inhibits the TGF-beta signaling pathway to drive cell proliferation in cervical cancer.
    Cancer Res. 2023 Jun 23:CAN-23-0067. doi: 10.1158/0008-5472.CAN-23-0067.
    >> Share

  17. ROSSI NM, Dai J, Xie Y, Wangsa D, et al
    Extrachromosomal Amplification of Human Papillomavirus Episomes Is a Mechanism of Cervical Carcinogenesis.
    Cancer Res. 2023;83:1768-1781.
    >> Share

    May 2023
  18. CAO K, Zhang G, Yang M, Wang Y, et al
    Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer.
    Cancer Res. 2023 May 12:CAN-22-3260. doi: 10.1158/0008-5472.CAN-22-3260.
    >> Share

  19. KELLIHER L, Lengyel E
    Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
    Cancer Res. 2023;83:1383-1385.
    >> Share

  20. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    >> Share

    April 2023
  21. LIU Y, Gusev A, Kraft P
    Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Cancer Res. 2023;83:1191-1202.
    >> Share

    February 2023
  22. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    >> Share

  23. FERRI-BORGOGNO S, Zhu Y, Sheng J, Burks JK, et al
    Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.
    Cancer Res. 2023 Feb 14:CAN-22-1821. doi: 10.1158/0008-5472.CAN-22-1821.
    >> Share

    January 2023
  24. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    >> Share

    December 2022
  25. JUNGLES KM, Green MD
    Fat Fuels the Fire in Cervical Cancer.
    Cancer Res. 2022;82:4513-4514.
    >> Share

  26. HAWKINS SM, Nephew KP
    Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Cancer Res. 2022;82:4511-4512.
    >> Share

  27. ALSINA-SANCHIS E, Mulfarth R, Moll I, Bohn S, et al
    Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages.
    Cancer Res. 2022;82:4414-4428.
    >> Share

    November 2022
  28. WANG CK, Chen TJ, Tan GYT, Chang FP, et al
    MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis.
    Cancer Res. 2022 Nov 10. pii: 710535. doi: 10.1158/0008-5472.CAN-22-1159.
    >> Share

    October 2022
  29. ATIYA HI, Frisbie L, Goldfeld E, Orellana T, et al
    Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation.
    Cancer Res. 2022 Oct 11. pii: 709712. doi: 10.1158/0008-5472.CAN-22-1294.
    >> Share

  30. MUHAMMAD N, Ruiz F, Stanley J, Rashmi R, et al
    Mono- and diunsaturated fatty acids sensitize cervical cancer to radiation therapy.
    Cancer Res. 2022 Oct 10. pii: 709678. doi: 10.1158/0008-5472.CAN-21-4369.
    >> Share

  31. CHAMBERS LM, Esakov Rhoades EL, Bharti R, Braley C, et al
    Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.
    Cancer Res. 2022 Oct 7. pii: 709668. doi: 10.1158/0008-5472.CAN-22-0455.
    >> Share

  32. WANG Y, Huang P, Wang BG, Murdock T, et al
    Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis.
    Cancer Res. 2022 Oct 7. pii: 709669. doi: 10.1158/0008-5472.CAN-22-1620.
    >> Share

  33. HO GY, Kyran EL, Bedo J, Wakefield MJ, et al
    Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin.
    Cancer Res. 2022 Oct 7. pii: 709667. doi: 10.1158/0008-5472.CAN-21-4012.
    >> Share

  34. LU X, Xin DE, Du JK, Zou QC, et al
    Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression.
    Cancer Res. 2022 Oct 5. pii: 709611. doi: 10.1158/0008-5472.CAN-22-0848.
    >> Share

    September 2022
  35. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    >> Share

    August 2022
  36. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    >> Share

    July 2022
  37. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    >> Share

    April 2022
  38. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    >> Share

    March 2022
  39. OSORIO JC, Zamarin D
    Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.
    Cancer Res. 2022;82:766-768.
    >> Share

  40. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    >> Share

    February 2022
  41. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    PGC1alpha/beta EXPRESSION PREDICTS THERAPEUTIC RESPONSE TO OXIDATIVE PHOSPHORYLATION INHIBITION IN OVARIAN CANCER.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    >> Share

    December 2021
  42. MANDAL G, Biswas S, Anadon CM, Yu X, et al
    IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer.
    Cancer Res. 2021 Dec 23. pii: 0008-5472.CAN-21-2376.
    >> Share

  43. O'CONNOR CM, Taylor SE, Miller KM, Hurst L, et al
    Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-1987.
    >> Share

    November 2021
  44. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    >> Share

  45. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    >> Share

    October 2021
  46. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    >> Share

    September 2021
  47. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    >> Share

  48. HENKLE TR, Lam B, Kung YJ, Lin J, et al
    Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
    Cancer Res. 2021;81:4560-4569.
    >> Share

    June 2021
  49. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    >> Share

    May 2021
  50. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016